Bristol-Myers Squibb: Aches and Pains
Take two Excedrins, and call Bristol in a couple years.
The folks at Bristol-Myers Squibb probably wish the drug giant still made Extra Strength Excedrin. They could all use a double dose to cope with the latest unpleasant development to slam the company: The board of directors' September 12 ouster of Bristol-Myers' embattled CEO. Bristol is now arguably the most down-on-its-luck company in a sector that has plenty of industry-wide problems.
To understand drug-company woes, and to see the light at the end of the industry's tunnel, look no further than Bristol-Myers. Some of what makes Bristol the industry poster child are things it brought on itself, but some of its problems afflict nearly all of its rivals. Start with a 2002 accounting scandal, in which the company was found to have been "channel stuffing" -- forcing inventory into its distribution channels to inflate sales. The company paid $800 million and agreed to supervision by a federal monitor. If it kept its nose clean until April 2007, charges would be dropped.
The monitor thought Bristol-Myers crossed the line this summer. Apparently, its dealings with Canadian drug maker Apotex to keep a generic version of Bristol's blockbuster blood-thinning drug, Plavix, off the market weren't kosher. The monitor persuaded the board to sack CEO Peter Dolan and general counsel Richard Willard.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Some analysts hailed Dolan's ouster as overdue because Bristol shares plummeted during his five-year tenure. The stock (symbol BMY) has fallen from the $70s in 2001 to a September 12 close of $24.32, up 4% on the day. In fact, it's been a tough period for almost all of the big pharmaceutical companies. They have been suffering from a lack of new drugs and intense competition from generics that hit the markets as soon as big pharma's patents expire.
Bristol-Myers is arguably in the worst shape of any of the majors. Profits have been weak, to put it charitably, and the company may have to cut its dividend (now at an annual rate of $1.12 per share). Analysts on average expect Bristol to earn $1.02 per share this year and $1.17 next year, according to Thomson First Call. That's down from a peak of $2.41 per share in 2001. Only three of 23 analysts polled by Thomson First Call rate Bristol-Myers a "buy" or "strong buy."
So, where's the light at the end of the tunnel? A long way off, but it's there. Homestead Value fund owns Bristol-Myers and other big pharma companies, but then, the fund holds stocks for ten years, on average. Co-manager Stuart Teach says you have to look past the noise in the market to find the true value of these companies.
In the late 1990s, Teach says, most analysts suggested that drug stocks could rise steadily forever. And why not? They had the fundamentals on their side: An aging population and the seemingly limitless ability of health-insurance providers to pay for all the drugs the baby boomers would need. Today, the population is still aging and somebody will still have to pay for all the drugs aging boomers will consume. "We fully believe that the underlying fundamentals at Bristol-Myers are intact," says Teach. "The latest news is not going to break the underlying fundamentals." And the strongest of those fundamentals is a track record of developing drugs that people need. The timing of Bristol's recovery is uncertain, but it almost certainly will recover some day.
-
Do You Pay Property Taxes in Tennessee? What You Need to Know in 2026Property Taxes State lawmakers are moving to ban state property taxes, but can they stop the local rate spike? Here's how 2026 could lower your Tennessee property tax bill.
-
Should You Be Investing in Emerging Markets?Economic growth, earnings acceleration and bargain prices favor emerging markets stocks right now.
-
Estate Planning When You Have a Skeleton in the ClosetWe asked estate planning experts how to keep transgressions secret, even after death.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
-
What the Rich Know About Investing That You Don'tPeople like Warren Buffett become people like Warren Buffett by following basic rules and being disciplined. Here's how to accumulate real wealth.
